SGD Pharma to showcase siliconized vials and ready-to-use solutions at CPHI Worldwide 2024

ITALY – SGD Pharma, a global leader in pharmaceutical packaging solutions, will unveil its latest innovations at the CPHI Worldwide 2024 event in Milan, Italy, from October 8 to 10.

The company will highlight its sustainability and pharmaceutical packaging advancements, focusing on its siliconized vials and ready-to-use (RTU) solutions designed to streamline drug manufacturing.

A major highlight of SGD Pharma’s exhibit is the launch of siliconized molded glass vials, the first of their kind to meet pharmaceutical standards.

This breakthrough protects sensitive, aggressive, and viscous drug products. The siliconized coating inside the vials minimizes drug interaction with the packaging, preserving the integrity and efficacy of medications.

In addition to the siliconized vials, SGD Pharma will showcase its Sterinity EZ-fill vials, a ready-to-use solution in Type I and Type II molded glass.

These RTU vials are designed to simplify the drug manufacturing process, offering pharmaceutical companies more flexibility and efficiency.

The comprehensive range of options allows customers to choose the best fit for their specific requirements, supporting faster time to market.

“Sustainability is at the heart of our innovations,” said Olivier Rousseau, CEO of SGD Pharma. “At CPHI 2024, we are showcasing solutions developed with our pharma and veterinary customers’ needs in mind, enabling them to bring their drugs to market quickly and safely.

“Our renewable energy initiatives, including upgrading the furnace at our Saint Quentin Lamotte (SQLM) plant in France and installing solar panels at our Vemula facility in India, reflect our commitment to decarbonization. We aim to cut emissions by 35% by 2030 and 65% by 2040.”

SGD Pharma’s sustainable focus extends beyond product innovation. The company has made significant strides in reducing its carbon footprint through investments in renewable energy and process improvements, underlining its commitment to a greener future.

As a participant in the UN Global Compact, SGD Pharma is dedicated to fostering sustainability throughout its operations.

Along with its vial innovations, SGD Pharma will also present new caps for Ensiemo syrup bottles and an expanded range of LabServices designed to support customers throughout the drug development and manufacturing processes.

Alliance for ready-to-use solutions

In related news, Gerresheimer, Stevanato Group, and SCHOTT Pharma have announced a strategic industry alliance, dubbed the “Alliance for RTU”, to promote the adoption of Ready-to-Use (RTU) vials and cartridges.

The alliance will highlight the advantages of RTU configurations over traditional bulk packaging for pharmaceutical companies, CMOs, and CDMOs.

The transition to RTU packaging presents several benefits, including reduced operational risks, enhanced flexibility, and improved efficiency.

RTU technology can streamline processes, boost productivity, and lower the total cost of ownership while ensuring compliance with stringent safety standards like EU GMP Annex 1.

“With advancements in RTU processing, the technology is now mature enough to improve efficiency and reduce costs significantly,” said Lukas Burkhardt, a member of the Gerresheimer management board.

This alliance will be officially introduced at the CPHI, where the three companies will showcase how RTU solutions can elevate the quality and efficiency of pharmaceutical production while supporting the growing demand for injectable medicines.

Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE